Abstract: The present invention relates to compositions comprising at least one purified PorA protein antigen and at least one purified FetA protein antigen. In particular, said PorA/FetA antigens are antigenically variable antigens comprising the variable regions of PorA/FetA. Specific combinations of PorA/FetA epitopes are presented for example in Table 3. The invention also relates to methods of immunisation comprising administering said compositions, and to methods for producing compositions. Preferably the compositions are purified protein compositions. Preferably the compositions are vaccine compositions.

Abstract: The present invention relates to compositions comprising at least one purified PorA protein antigen and at least one purified FetA protein antigen. In particular, said PorA/FetA antigens are antigenically variable antigens comprising the variable regions of PorA/FetA. Specific combinations of PorA/FetA epitopes are presented for example in Table 3. The invention also relates to methods of immunization comprising administering said compositions, and to methods for producing compositions. Preferably the compositions are purified protein compositions. Preferably the compositions are vaccine compositions.

Abstract: The present invention provides a method of immunizing a subject against a disease caused by Neisseria meningitidis, comprising administering to the subject a primer composition comprising a meningococcal outer membrane vesicle preparation, and a booster composition comprising a meningococcal protein antigen preparation. Vaccine combinations comprising primer and booster compositions and associated uses are also provided.

Abstract: The present invention relates to a composition comprising at least one purified Opa HV 1 protein epitope and at least one purified Opa HV2 protein epitope. The epitopes are preferably purified protein epitopes, preferably recombinant epitopes. The composition is preferably a pharmaceutical composition, more preferably a vaccine composition. The invention also relates to methods of immunisation and to specific formulations presented in the tables, and to novel nucleic acids encoding Opa alleles.

Abstract: The present invention relates to compositions comprising at least one purified PorA protein antigen and at least one purified FetA protein antigen. In particular, said PorA/FetA antigens are antigenically variable antigens comprising the variable regions of PorA/FetA. Specific combinations of PorA/FetA epitopes are presented for example in Table 3. The invention also relates to methods of immunisation comprising administering said compositions, and to methods for producing compositions. Preferably the compositions are purified protein compositions. Preferably the compositions are vaccine compositions.